ACAngel A. Cobo

Angel A. Cobo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Angel A. Cobo has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Annaliese K. Franz

    Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, California 95616, United States

    3 shared publications
  • Andrew Hyland

    Roswell Park Comprehensive Cancer Center, Roswell Park Cancer Institute, Buffalo, NY

    1 shared publication
  • B Rey De Castro

    Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA

    1 shared publication
  • Baoyun Xia

    Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention , Atlanta, GA

    1 shared publication
  • Benjamin C Blount

    Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA

    1 shared publication
  • Benjamin Wigman

    Department of Chemistry, One Shields Ave, University of California, Davis, California 95616, United States

    1 shared publication

Latest Publications

  • Engineered Silyl Lipids to Modulate Liposome and Lipid Nanoparticle Properties for mRNA Delivery

    by Leah A. Patterson, David A. Coppage, Sydney M. Figueroa, Angel A. Cobo, Henriette O’gEen, David J. Segal, Annaliese K. Franz

    The design of amphiphilic lipid structures can be used to modulate key properties for diverse applications in biology and nanomaterials. We have engineered a structurally diverse class of amphiphilic silyl lipids using a hydrosilylation reaction as the key step to access lipids that vary the silyldimethyl position, branching, length, and substituents in the lipid tail. We demonstrate that the size, zeta potential, rRNA encapsulation, stability, bilayer fluidity, and mRNA transfection are controlled by varying the structure of the silyl lipid tail. Five silyl lipids exhibit high encapsulation, and three feature enhanced stability and transfection in HEK293T cells relative to DOTAP as a classic reference lipid. Incorporation of a branching silyldimethyl group (in place of a cis alkene or methylene) increases bilayer fluidity in liposomes.These results support the idea that incorporating a silyldimethyl group and accessing diverse lipid structures can control liposome properties and mRNA delivery, showing promise for using silyl lipid structures in other biology and biomaterial applications.


  • Ligand-Accelerated Catalysis in Scandium(III)-Catalyzed Asymmetric Spiroannulation Reactions

    by Nicolas R. Ball-Jones, Angel A. Cobo, Brittany M. Armstrong, Benjamin Wigman, James C. Fettinger, Jason E. Hein, Annaliese K. Franz


  • Top Cited Papers

    Recent advances in organocatalytic asymmetric multicomponent cascade reactions for enantioselective synthesis of spirooxindoles

    by Yongchao Wang, Angel A. Cobo, Annaliese K. Franz

    Catalytic asymmetric MCCRs for enantioselective synthesis of spirooxindoles by using chiral phosphoric acids, amines, bifunctional thiourea/squaramides and metal-based reagents as catalysts.


  • Open Access

    Tobacco-Specific Nitrosamines (NNAL, NNN, NAT, and NAB) Exposures in the US Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013–2014)

    by Baoyun Xia, Benjamin C Blount, Tonya Guillot, Christina Brosius, Yao Li, Dana M Van Bemmel, Heather L Kimmel, Cindy M Chang, Nicolette Borek, Kathryn C Edwards, et al.

    The tobacco-specific nitrosamines (TSNAs) are an important group of carcinogens found in tobacco and tobacco smoke. To describe and characterize the levels of TSNAs in the Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013–2014), we present four biomarkers of TSNA exposure: N′-nitrosonornicotine, N′-nitrosoanabasine, N′-nitrosoanatabine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) which is the primary urinary metabolite of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. We measured total TSNAs in 11 522 adults who provided urine using automated solid-phase extraction coupled to isotope dilution liquid chromatography–tandem mass spectrometry. After exclusions in this current analysis, we selected 11 004 NNAL results, 10 753 N′-nitrosonornicotine results, 10 919 N′-nitrosoanatabine results, and 10 996 N′-nitrosoanabasine results for data analysis. Geometric means and correlations were calculated using SAS and SUDAAN. TSNA concentrations were associated with choice of tobacco product and frequency of use. Among established, every day, exclusive tobacco product users, the geometric mean urinary NNAL concentration was highest for smokeless tobacco users (993.3; 95% confidence interval [CI: 839.2, 1147.3] ng/g creatinine), followed by all types of combustible tobacco product users (285.4; 95% CI: [267.9, 303.0] ng/g creatinine), poly tobacco users (278.6; 95% CI: [254.9, 302.2] ng/g creatinine), and e-cigarette product users (6.3; 95% CI: [4.7, 7.9] ng/g creatinine). TSNA concentrations were higher in every day users than in intermittent users for all the tobacco product groups. Among single product users, exposure to TSNAs differed by sex, age, race/ethnicity, and education. Urinary TSNAs and nicotine metabolite biomarkers were also highly correlated. We have provided PATH Study estimates of TSNA exposure among US adult users of a variety of tobacco products. These data can inform future tobacco product and human exposure evaluations and related regulatory activities.